ArticleImmunology and cell biology2025
Exploratory analyses of leukocyte responses in hospitalized patients treated with ozanimod following a severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) infection.
Olivier Courtemanche, Pascale Blais-Lecours, Sylvie Lesage, Geneviève Chabot-Roy, Lise Coderre, Marie-Renée Blanchet, Nathalie Châteauvert, François Lellouche, David Marsolais
Abstract read
In one paragraphArticle in Immunology and cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Olivier CourtemancheCentre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec, QC, Canada.
Pascale Blais-LecoursCentre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec, QC, Canada.
Sylvie LesageCentre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.
Geneviève Chabot-RoyCentre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.
Lise CoderreCentre de Recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.
Marie-Renée BlanchetCentre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec, QC, Canada.
Nathalie ChâteauvertCentre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec, QC, Canada.
François LelloucheCentre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec, QC, Canada.
David MarsolaisCentre de recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval, Québec, QC, Canada.
Funding
Bristol-Myers Squibb Canada RPC1063-CL-COV19-PI-14057Fonds Alphonse L'Espérance de la Fondation de l'IUCPQ
6 · The paper itselfAbstract
Sphingosine-1-phosphate receptor 1 (S1P
Indexed as
COVID-19COVID-19 Drug TreatmentLeukocytesOxadiazolesSARS-CoV-2AdultAgedAntibodies, ViralChemokine CCL2CytokinesFemaleHospitalizationHumansImmunity, HumoralIndansMaleAntibodies, ViralCCL2 protein, humanChemokine CCL2CytokinesIndansOxadiazolesozanimodanti–SARS‐CoV‐2 antibodiesclinical trialCOVID‐19monocytesS1P
Identifiers
PMID40025871
PMCPMC12108697
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390